Leading the Future of Intracellular Delivery

We have designed the Feldan Shuttle, a versatile biotechnology that enables safe and efficient delivery of therapeutic compounds into cells. By giving access to intracellular space, this unique technology is unlocking the potential of therapeutics that target intracellular components and contributes to the development of revolutionary treatments.

From Design to Delivery

Rationally designed from natural cell-penetrating peptides and endosomal leakage domains, the Feldan Shuttle is a short peptide that successfully circumvents endosomal entrapment. The Shuttle was engineered to perform highly effective and safe cytoplasmic delivery of multiple types of therapeutics, ranging from small molecules to proteins. Using our technology, we deliver biological compounds for which there are no other efficient delivery methods.

Membrane Interaction

The Shuttle interacts strongly with the membrane to initiate the permeabilization process.

Endosomal Leakage

While the Shuttle remains in the membrane, the free therapeutic compound translocates to the cytoplasm.

Characteristics of the Feldan Shuttle

The Feldan Shuttle provides a unique way to deliver therapeutic compounds inside cells and is allowing the development of next-generation therapies.

Peptide-based
Fast degradation
No toxic metabolites
Safe for in vivo use
Delivery of peptides, proteins and antisense oligonucleotides (ASOs)
Circumvents endosomal entrapment
Performs fast delivery on multiple cell types, ex vivo and in vivo

Correcting Diseases by Modulating Intracellular Pathways

The Feldan Shuttle allows untapped and highly specific therapeutics compounds to access intracellular pathways that can be targeted for therapeutic interventions. The versatility of the technology translates into multiple strategies to correct diseases:

Repressing Pathogenic Pathways

Having access to the intracellular space allows the targeting and correction of dysregulated proteins and signalling pathways associated with diseases.

Supplying Missing Proteins

The Feldan Shuttle allows the development of a new generation of therapies for diseases caused by the absence of intracellular proteins.

Rewriting Impaired Genes

The Feldan Shuttle allows the delivery of gene-editing nucleases in their active protein form. This allows precise and safe correction of impaired genes.

Publications

Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo.

Katarina Kulhankova, Soumba Traore, Xue Cheng, Hadrien Benk-Fortin, Stéphanie Hallée, Mario Harvey, Joannie Roberge, Frédéric Couture, Sajeev Kohli, Thomas J. Gross, David K. Meyerholz, Garrett R. Rettig, Bernice Thommandru, Gavin Kurgan, Christine Wohlford-Lenane, Dennis J. Hartigan-O’Connor, Bradley P. Yates, Gregory A. Newby, David R. Liu, Alice F. Tarantal, David Guay & Paul B. McCray Jr., Nat Commun 14, 8051 (2023). doi: 10.1038/s41467-023-43904-w. PMID: 38052872

Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia.

Krishnamurthy S, Wohlford-Lenane C, Kandimalla S, Sartre G, Meyerholz DK, Théberge V, Hallée S, Duperré AM, Del'Guidice T, Lepetit-Stoffaes JP, Barbeau X, Guay D, McCray PB Jr., Nat Commun. 2019 Oct 28;10(1):4906. doi: 10.1038/s41467-019-12922-y. PMID: 31659165

Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells.

Del'Guidice T, Lepetit-Stoffaes JP, Bordeleau LJ, Roberge J, Théberge V, Lauvaux C, Barbeau X, Trottier J, Dave V, Roy DC, Gaillet B, Garnier A, Guay D. PLoS One. 2018 Apr 4;13(4):e0195558. doi: 10.1371/journal.pone.0195558. eCollection 2018. PMID:29617431